Flis et al. (2019) demonstrated that the PAK1 inhibitor combined with BCR-ABL1 tyrosine kinase inhibitor displayed synergistic effect against chronic myeloid leukemia cells. Siekmann et al. (2018) also reported that combined inhibition of PAK1 and receptor tyrosine represented a valuable therapeutic strategy in childhood acute lymphoblastic leukemia (ALL). Here, PAK1 is linked to acute lymphoblastic leukemia.